PEPTIDE DATABASE
Peptide Database
265 therapeutic peptides with research summaries, clinical findings, and regulatory status.
METABOLIC
FDA APPROVED
Semaglutide (Ozempic/Wegovy)
METABOLIC
FDA APPROVED
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
METABOLIC
FDA APPROVED
Healing Blend
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
METABOLIC
FDA APPROVED
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
FDA APPROVED
Liraglutide (Saxenda/Victoza)
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
METABOLIC
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
FDA APPROVED
KLOW
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
RECOVERY
RESEARCH PHASE
DSIP (Delta Sleep-Inducing Peptide)
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
RECOVERY
RESEARCH PHASE
TB-500 (Thymosin Beta-4)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
RECOVERY
RESEARCH PHASE
Pentosan Polysulfate (Elmiron)
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
RECOVERY
RESEARCH PHASE
GHK-Cu
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
HORMONE
FDA APPROVED
Tesamorelin (Egrifta)
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
HORMONE
FDA APPROVED
Ipamorelin
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
HORMONE
FDA APPROVED
PT-141 (Bremelanotide / Vyleesi)
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
HORMONE
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
REPRODUCTIVE
FDA APPROVED
Leuprolide (Lupron)
REPRODUCTIVE
FDA APPROVED
Ganirelix
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
REPRODUCTIVE
FDA APPROVED
Goserelin (Zoladex)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
REPRODUCTIVE
FDA APPROVED
Carbetocin
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
REPRODUCTIVE
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
COGNITIVE
FDA APPROVED
P21 (Peptide)
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
COGNITIVE
FDA APPROVED
Selank
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
COGNITIVE
FDA APPROVED
Dihexa
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
COGNITIVE
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
LONGEVITY
FDA APPROVED
Epithalon (Epitalon)
LONGEVITY
FDA APPROVED
NAD+ Precursors (NMN)
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
LONGEVITY
FDA APPROVED
MOTS-c
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
LONGEVITY
FDA APPROVED
SS-31 (Elamipretide)
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
LONGEVITY
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
IMMUNE
FDA APPROVED
KPV
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
IMMUNE
FDA APPROVED
LL-37
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
IMMUNE
FDA APPROVED
Splenopentin
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
IMMUNE
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
PERFORMANCE
FDA APPROVED
PEG-MGF
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
PERFORMANCE
FDA APPROVED
IGF-1 LR3 (Long-Arg3)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
PERFORMANCE
FDA APPROVED
Follistatin-344
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
PERFORMANCE
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
BONE
FDA APPROVED
Vosoritide (Voxzogo)
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
BONE
FDA APPROVED
Abaloparatide (Tymlos)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
BONE
FDA APPROVED
PTH (1-34) Analogs
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
BONE
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
RENAL
FDA APPROVED
Desmopressin (DDAVP)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
RENAL
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
CARDIOVASCULAR
FDA APPROVED
Eptifibatide (Integrilin)
CARDIOVASCULAR
FDA APPROVED
Serelaxin (Relaxin-2)
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
CARDIOVASCULAR
FDA APPROVED
Nesiritide (Natrecor)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
CARDIOVASCULAR
FDA APPROVED
Carperitide (h-ANP)
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
CARDIOVASCULAR
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
HEMATOLOGY
FDA APPROVED
Bivalirudin (Angiomax)
HEMATOLOGY
FDA APPROVED
Peginesatide (Omontys)
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
HEMATOLOGY
FDA APPROVED
Romiplostim (Nplate)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
HEMATOLOGY
FDA APPROVED
Eltrombopag Peptide Mimetics
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
HEMATOLOGY
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
ONCOLOGY
FDA APPROVED
Carfilzomib (Kyprolis)
ONCOLOGY
FDA APPROVED
Triptorelin (Trelstar)
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
ONCOLOGY
FDA APPROVED
Bortezomib (Velcade)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
ONCOLOGY
FDA APPROVED
Histrelin (Vantas)
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
ONCOLOGY
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
GASTROINTESTINAL
FDA APPROVED
Octreotide (Sandostatin)
GASTROINTESTINAL
FDA APPROVED
Larazotide
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
GASTROINTESTINAL
FDA APPROVED
Pasireotide (Signifor)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
GASTROINTESTINAL
FDA APPROVED
Motilin
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
GASTROINTESTINAL
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
PAIN
FDA APPROVED
Endomorphin-1
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
PAIN
FDA APPROVED
Dynorphin A
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
PAIN
FDA APPROVED
Endomorphin-2
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabling albumin binding and a…
PAIN
FDA APPROVED
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
DERMATOLOGY
FDA APPROVED
Afamelanotide (Scenesse)
DERMATOLOGY
FDA APPROVED
Argireline (Acetyl Hexapeptide-8)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…